Grufity logoGrufity logo

BHVN

Market Closed

Biohaven Pharmaceutical Holding Company Ltd

BHVN Stock Price

RSI Chart

Valuation

Market Cap

10.9B

Price/Earnings

-11.67

Price/Sales

12.62

Price/Cashflow

-19.52

MarketCap/EBT

-11.93

Price/Sales

Profitability

EBT Margin

-105.78%

Return on Equity

-694.16%

Return on Assets

-67.07%

Fundamentals

Revenue

Revenue (TTM)

859.7M

Revenue Y/Y

131.43%

Revenue Q/Q

-32.55%

Earnings

Earnings (TTM)

-929.8M

Earnings Y/Y

-109.8%

Earnings Q/Q

-278.01%

Price Action

Last 7 days

-9.7%

Last 30 days

2.1%

Last 90 days

-89.9%

Trailing 12 Months

-87.5%

Financial Health

Current Ratio

1.75

Debt/Equity

5.14

Debt/Cashflow

-0.73

Investor Care

Shares Dilution (1Y)

9.32%

Diluted EPS (TTM)

-14.81

Peers (Alternatives to Biohaven Pharmaceutical Holding Company)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Biohaven Pharmaceutical Holding Company

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue16.6%860738463308190
Gross Profit53.3%371242145
Operating Expenses12.0%1,075960887
  S&GA Expenses10.3%862781714616572
  R&D Expenses37.8%514373361344315
Earnings Before Taxes-34.8%-909.40-674.41-843.32-856.07-874.18
Net Income-33.1%-929.78-698.51-846.59-865.14-888.51
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets1.1%1,3861,3721,0771,131846
  Current Assets0.3%1,1741,171876944667
    Cash Equivalents39.5%236169172501306
  Inventory16.7%10791817564
  Net PPE8.2%1615151011
Liabilities19.2%2,1921,8381,7601,6621,242
  Current Liabilities16.6%672576534462399
  Long Term Debt20.6%765634627619274
    LT Debt, CurrentNaN%-----
    LT Debt, Non Current125.9%619274---
  Retained Earnings-16.3%-3,143.54-2,702.15-2,585.75-2,386.57-2,214.76
  Additional Paid-In Capital28.9%167130170165142
Accumulated Depreciation-5----
Shares Outstanding0.8%7171676565
Minority Interest-12.1%-4.62-4.13-3.63-3.23-2.72
Float-4,260----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations14.3%-556.06-649.07-831.10-849.95-809.06
  Share Based Compensation9.2%175160127116103
Cashflow From Investing4.8%-321.38-337.4927206-84.76
Cashflow From Financing16.9%809692845827938

Risks

What is the probability of a big loss on BHVN?

89.5%


Probability that Biohaven Pharmaceutical Holding Company stock will be more than 20% underwater in next one year

87.8%


Probability that Biohaven Pharmaceutical Holding Company stock will be more than 30% underwater in next one year.

53.4%


Probability that Biohaven Pharmaceutical Holding Company stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BHVN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biohaven Pharmaceutical Holding Company was unfortunately bought at previous high price.

Returns

Cumulative Returns on BHVN

-10.8%


5-Year Cumulative Returns

-36.6%


3-Year Cumulative Returns

What are the long-term rolling returns for BHVN?

FIve years rolling returns for Biohaven Pharmaceutical Holding Company.

Which funds bought or sold BHVN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
SOLD OFF
-100
-238,000
-
-%
2022-11-23
Toroso Investments, LLC
ADDED
5.03
28,000
335,000
0.01%
2022-11-22
Mint Tower Capital Management B.V.
SOLD OFF
-100
-1,343,000
-
-%
2022-11-21
Parallax Volatility Advisers, L.P.
REDUCED
-86.51
-2,506,000
408,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.12
293,000
11,629,000
0.02%
2022-11-18
Industrial Alliance Investment Management Inc.
SOLD OFF
-100
-5,212,000
-
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-15,000
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-84,000
-
-%
2022-11-15
SeaCrest Wealth Management, LLC
SOLD OFF
-100
-266,000
-
-%
2022-11-15
ALGERT GLOBAL LLC
ADDED
38.64
884,000
2,901,000
0.17%

1–10 of 41

Latest Funds Activity

Are funds buying BHVN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BHVN

Biohaven Pharmaceutical Holding Company News

GuruFocus.com

Top 5 3rd Quarter Trades of Values First Advisors, Inc..2 days ago

BHVN Fair Value

Recent SEC filings of Biohaven Pharmaceutical Holding Company

View All Filings
Date Filed Form Type Document
Oct 14, 2022
15-12G
15-12G
Oct 05, 2022
4
Insider Trading
Oct 04, 2022
25-NSE
25-NSE
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading

Latest Insider Trading transactions for BHVN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-03
CHILDS JOHN W
GIVEN BACK TO IS
-1,485,000
148.5
-10,000
-
2022-10-03
Coric Vlad
GIVEN BACK TO IS
-13,669,400
148.5
-92,050
Chief Executive Officer
2022-10-03
HUGIN ROBERT J
GIVEN BACK TO IS
-430,650
148.5
-2,900
-
2022-10-03
Bailey Gregory
GIVEN BACK TO IS
-383,674,000
148.5
-2,583,660
-
2022-10-03
Coric Vlad
GIVEN BACK TO IS
-2,840,800
148.5
-19,130
Chief Executive Officer
2022-10-03
Stock Elyse
GIVEN BACK TO IS
-1,646,860
148.5
-11,090
Chief Medical Officer
2022-10-03
Stock Elyse
GIVEN BACK TO IS
-798,039
148.5
-5,374
Chief Medical Officer
2022-10-03
Engelhart James
GIVEN BACK TO IS
-2,361,150
148.5
-15,900
Strategic Advisor
2022-10-03
Conway Charles
GIVEN BACK TO IS
-3,320,760
148.5
-22,362
Chief Scientific Officer
2022-10-03
Tilton John
GIVEN BACK TO IS
-239,679
148.5
-1,614
Chief Commercial Officer

1–10 of 50

BHVN Income Statement

2022-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:  
Total revenues$ 318,852$ 43,823
Operating expenses:  
Cost of sales26,34212,862
Research and development expense119,099107,111
Selling, general and administrative227,243159,523
Total operating expenses372,684279,496
Loss from operations(53,832)(235,673)
Other income (expense):  
Interest expense(17,216)(7,731)
Interest expense on mandatorily redeemable preferred shares(7,917)(7,943)
Interest expense on liability related to sale of future royalties(17,314)(13,508)
Change in fair value of derivatives3,604(210)
Gain from equity method investment05,261
Other income (expense), net81(1,700)
Total other expense, net(38,762)(25,831)
Loss before provision for income taxes(92,594)(261,504)
Provision for income taxes24,3033,824
Net loss(116,897)(265,328)
Net loss attributable to non-controlling interests498360
Deemed dividend upon repurchase of preferred shares in consolidated subsidiary(92,673)0
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.$ (209,072)$ (264,968)
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - basic (in dollars per share)$ (2.97)$ (4.27)
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - diluted (in dollars per share)$ (2.97)$ (4.27)
Weighted average common shares outstanding - basic (shares)70,332,27462,040,715
Weighted average common shares outstanding - diluted (shares)70,332,27462,040,715
Comprehensive loss:  
Net loss$ (116,897)$ (265,328)
Other comprehensive (loss) income, net of tax(2,325)95
Comprehensive loss(119,222)(265,233)
Less: comprehensive loss attributable to non-controlling interests498360
Comprehensive loss attributable to Biohaven Pharmaceutical Holding Company Ltd.(118,724)(264,873)
Product revenue, net  
Revenues:  
Total revenues123,59043,823
Collaboration and other revenue  
Revenues:  
Total revenues$ 195,262$ 0

BHVN Balance Sheet

2022-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 169,065$ 171,945
Marketable securities433,410192,648
Trade receivable, net328,342308,269
Inventory91,28180,608
Prepaid expenses104,89188,838
Other current assets44,09633,946
Total current assets1,171,085876,254
Property and equipment, net14,53414,690
Intangible assets, net55,91056,438
Other assets130,188129,830
Total assets1,371,7171,077,212
Current liabilities:  
Accounts payable56,20251,683
Accrued expenses and other current liabilities457,412420,019
Current portion of mandatorily redeemable preferred shares62,50062,500
Total current liabilities576,114534,202
Long-term debt634,106626,720
Liability related to sale of future royalties, net377,998367,645
Mandatorily redeemable preferred shares, net162,994155,737
Derivative liability9,12013,110
Obligation to perform R&D services36,01650,571
Other long-term liabilities41,78212,236
Total liabilities1,838,1301,760,221
Commitments and contingencies
Contingently redeemable non-controlling interests060,000
Shareholders’ deficit:  
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 70,540,802 and 66,933,531 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively2,112,6861,676,792
Additional paid-in capital129,580169,656
Accumulated other comprehensive loss(2,398)(73)
Accumulated deficit(2,702,154)(2,585,755)
Total shareholders’ deficit attributable to Biohaven Pharmaceutical Holding Company Ltd.(462,286)(739,380)
Non-controlling interests in consolidated subsidiaries(4,127)(3,629)
Total shareholders' deficit(466,413)(743,009)
Total liabilities and shareholders’ deficit$ 1,371,717$ 1,077,212